If you or a loved one is about to use or is using docetaxel for prostate cancer and are very concerned about the possible side effects of docetaxel, I believe this article will help you.
Here are a few key points highlighted in this article:
- Docetaxel is an effective chemotherapy regimen for metastatic desmoresistant prostate cancer, but the risk of side effects should be considered when used in patients of advanced age.
- The most common adverse effect of docetaxel chemotherapy is neutropenia, which predisposes patients to infections.
- Docetaxel is very unlikely to cause a serious allergic reaction, but it may lead to death if left untreated.
- Other adverse reactions to docetaxel, such as fluid retention, fatigue, and peripheral neuropathy, have a low incidence and are managed.
- Patients with other comorbidities, such as diabetes, gout, heart disease, and liver disease, should inform their doctor of their medical history before chemotherapy so that the doctor can decide whether to use docetaxel and how to adjust the dose.
In 2004, the U.S. Food and Drug Administration (FDA) approved docetaxel as a treatment for patients with castration resistant prostate cancer (CRPC). In recent years, a number of large clinical trials have further confirmed the reliable efficacy of docetaxel.
The latest version of the 2018 National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer clearly recommend docetaxel in combination with a hormonal agent such as prednisone or dexamethasone as a chemotherapy option for patients with stage M1 destructive prostate cancer.
While docetaxel chemotherapy can help slow tumor progression and prolong survival in prostate cancer patients, the majority of prostate cancer patients are elderly and often have a combination of underlying conditions (e.g., diabetes, heart disease, etc.). Therefore, how to ensure the safety of chemotherapy and maximize the quality of life while improving the efficacy of chemotherapy has become a concern for many patients and physicians.
According to the latest “Consensus on the Safety of Chemotherapy for Prostate Cancer” (2018), the most common adverse effect of docetaxel chemotherapy for prostate cancer is neutropenia, and other adverse effects, such as allergic reactions, fluid retention, fatigue, and peripheral neuropathy, are less common.
The following is a summary of the safety issues and recommendations from this consensus regarding docetaxel.
Myelosuppression
What are the clinical manifestations of myelosuppression?
Patients may experience leukopenia, decreased neutrophils, anemia, and decreased platelets after treatment with docetaxel. The most prominent of these is neutropenia, but neutropenia is reversible.
What should I do if I develop bone marrow suppression?
What should I do if I have bone marrow suppression?
During chemotherapy, if there is a significant drop in white blood cell or neutrophil counts, your doctor may discontinue chemotherapy and give colony-stimulating factor therapy, along with antibiotics to prevent infection if there is fever. If anemia and decreased blood counts occur, they are graded according to severity.
Is there a way to prevent bone marrow suppression?
Can myelosuppression be prevented?
Before chemotherapy, the doctor will evaluate the patient’s bone marrow and may forgo chemotherapy if his or her neutrophil count is found to be low. For patients receiving chemotherapy, blood tests are reviewed promptly during chemotherapy to allow for early detection of the onset of chemotherapy-related myelosuppression.
Allergic reactions
Anaphylaxis is another serious side effect of docetaxel chemotherapy that may even lead to death if not managed clinically and appropriately.
What are the clinical manifestations of allergic reactions?
What are the clinical signs of an allergic reaction?
Symptoms of allergic reactions are classified as mild, moderate, or severe.
- Mild symptoms: localized skin reactions only, such as itching, flushing, and rash;
- Moderate symptoms: generalized pruritus, increased flushing or rash, mild dyspnea, etc.
- Severe symptoms: severe respiratory, circulatory, and rash reactions such as bronchospasm, hypotension, generalized urticaria, and angioedema.
How to manage allergic reactions?
Depending on the severity of the allergic reaction, the doctor will take different measures to manage it:
- Mild allergic reaction: The doctor will slow down the docetaxel drip until symptoms return and monitor it at the bedside. After the symptoms have completely resolved, the titration is then completed at the original planned infusion rate.
- Moderate allergic reaction: The physician will immediately stop the docetaxel drip, administer intravenous antihistamines and glucocorticoids, and monitor the patient at the bedside until symptoms improve.
- Severe anaphylaxis: The physician will immediately stop the docetaxel infusion, ensure that intravenous access is maintained, and administer intravenous antihistamines and glucocorticosteroids. Immediate injection of epinephrine if anaphylaxis occurs. If hypotension persists, intravenous antihypertensive medication is administered and the patient’s airway is ensured to be open and oxygen is administered. If life-threatening airway obstruction occurs, immediate tracheal intubation or bedside tracheotomy is performed and the patient’s vital signs and oxygen saturation are monitored until symptoms improve.
General adverse reactions
Drug extravasation
In case of drug extravasation, the patient should rest in bed, elevate the affected limb, and avoid activity; the physician will apply a local cold compress or close it with lidocaine. In the interval between chemotherapy sessions, magnesium sulfate wet compresses or physical therapy may be used.
Tell your doctor immediately if you notice red or painful, blistering, and purple skin at the injection site, a condition that usually requires discontinuation of the drug.
Nausea and vomiting
Patients may experience gastrointestinal symptoms such as nausea and vomiting after docetaxel chemotherapy, most often within 2 to 24 hours after chemotherapy, and most can be prevented by using antiemetic medications.
Body fluid retention
Docetaxel-induced fluid retention is usually peripheral edema, usually starting in the lower extremities and possibly progressing to the whole body, with weight gain of 3 kg or more. It usually occurs after 3 to 5 weeks of chemotherapy, but resolves after discontinuation of the drug. Patients need to be aware of:
- Any significant weight gain during chemotherapy;
- Whether there is swelling of the fingers, ankles, or abdomen, whose may be a precursor to fluid retention.
If fluid retention occurs, the doctor will treat it with diuretics.
Hair loss
Docetaxel can cause hair loss, which usually occurs within days to weeks after chemotherapy, but the hair loss is reversible and new hair can usually regrow six months after stopping the drug. Therefore, patients should be aware that:
- Use a mild shampoo and reduce the frequency of shampooing;
- Keeping the area around the bed clean, either with a cap or cotton head cover;
- Increase the intake of high-protein diet to favor hair growth.
Fatigue
Docetaxel chemotherapy can cause fatigue, mainly in the form of weakness and fatigue; depressed mood and poor concentration. Fatigue is usually associated with complications such as pain, anemia, malnutrition, sleep disturbances, and low functional status, so these problems can be addressed to reduce fatigue. In addition, patients should maintain a moderate amount of exercise and avoid prolonged bed rest (more than half a day). Once fatigue occurs, the following measures can be considered:
- Physical therapy, such as massage therapy, to help relieve fatigue;
- A balanced diet to maintain good nutritional status;
- Improving the quality of rest and sleep, such as a hot bath before bed can help with sleep;
In addition, family members should pay attention to the patient’s mental health and consult a psychologist if necessary to reduce the psychological stress caused by cancer; sometimes fatigue is related to psychological problems.
Neurotoxicity
Docetaxel can cause neurotoxicity (e.g., numbness in the hands and feet), mostly 24 to 72 hours after chemotherapy, and the longer the drug is administered, the higher the incidence of neurotoxicity. Symptomatic management is usually sufficient, and the doctor will reduce the dose in the presence of severe peripheral neurologic symptoms.
Dermal toxicity
Docetaxel can cause skin toxicity with a rash commonly on the hands and feet, but also on the arms, face, and chest. Symptomatic management is usually sufficient. In the presence of severe peripheral nerve symptoms, the doctor will reduce the dose of the drug.
In summary, it is important for prostate cancer patients and their families who are about to receive or are receiving docetaxel to learn about the possible side effects of chemotherapy and how to deal with them in advance. Patients or family members should also learn to observe various abnormal changes in their bodies, recognize and judge the signs of various side effects, and inform their doctors in time for treatment.
Related articles: